Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT200 in Type 2B von Willebrand Disease with Thrombocytopenia
2023-000044-34Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Jun 2023
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rondaptivon pegol in von Willebrand disease type 2B (VWD2B), sponsored by Medical University of Vienna. Primary endpoints: Platelet counts and Monthly bleeding events. Started Jun 2023; status: active.
02
Drugs
rondaptivon pegol
03
Conditions
von Willebrand disease type 2B (VWD2B)
Beyond the preview
Go deeper on 2023-000044-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000044-34.